NCT05900414 RAPID AFib Decision Aid for Stroke Prevention in Atrial Fibrillation
| NCT ID | NCT05900414 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calgary |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2025-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-04-01 with a primary completion date of 2025-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this pilot clinical trial is to evaluate the utility of a new electronic patient decision aid for stroke prevention therapy in patients with atrial fibrillation. The main questions it aims to answer are: Is the patient decision aid acceptable to both patients and physicians? Does the patient decision aid lead to more effective shared decision-making than standard care among patients with atrial fibrillation who are considering stroke prevention therapy? Participants with a recent diagnosis of atrial fibrillation will be enrolled before an upcoming specialist physician visit. Researchers will compare a pre-visit intervention consisting of standard educational materials plus use of the patient decision aid to educational materials alone to see if using the decision aid results in improved shared decision making during the clinic visit.
Eligibility Criteria
Inclusion Criteria: * Non-valvular AF diagnosed within 12 months, with any level of stroke risk assessed by CHA2DS2-VASc score. * Age 18 or older * Either no OAC treatment or treated for less than 90 days. * Initial specialist AF visit scheduled in 7-30 days. Exclusion Criteria: * Valvular AF, defined, per Canadian Cardiovascular Society Guidelines, as AF in the presence of mechanical heart valves, rheumatic mitral stenosis, or moderate to severe nonrheumatic mitral stenosis. * Currently prescribed dual antiplatelet therapy (ASA plus either clopidogrel, ticagrelor, or prasugrel) for an indication other than AF. * Has an independent, non-AF indication for oral anticoagulation. * Has a non-modifiable impediment to effective use of web-based tools. Examples include lack of internet access, lack of English literacy (Grade 5 level).
Contact & Investigator
Stephen B Wilton, MD
PRINCIPAL INVESTIGATOR
University of Calgary
Frequently Asked Questions
Who can join the NCT05900414 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05900414 currently recruiting?
Yes, NCT05900414 is actively recruiting participants. Contact the research team at sbwilton@ucalgary.ca for enrollment information.
Where is the NCT05900414 trial being conducted?
This trial is being conducted at Calgary, Canada, Calgary, Canada.
Who is sponsoring the NCT05900414 clinical trial?
NCT05900414 is sponsored by University of Calgary. The principal investigator is Stephen B Wilton, MD at University of Calgary. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.